Pharmacokinetics of Riluzole in Beagle Dogs

Abstract

Background Riluzole is a benzothiazole anticonvulsant used in the treatment of patients with amyotrophic lateral sclerosis and it is being investigated for clinical use in patients with spinal cord injury. The present study evaluated the pharmacokinetics of riluzole in beagle dogs after oral dose administration.

Methods The oral doses (1.5, 5, 15 and 50 mg/kg) of riluzole were administered to beagle dogs and blood samples were collected from 0 h to 24 h post drug administration. Riluzole was quantified by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).

Results The method was sensitive, precise, accurate and selective to riluzole quantification in plasma of beagle dogs. The pharmacokinetics following oral administration was linear from 1.5 to 15 mg/kg and the t_1/2 was 2.16, 1.5, 1.8 and 3.0 h after oral administration of 1.5, 5.0, 15 and 50 mg/kg riluzole.

Conclusion The riluzole pharmacokinetics was linear up to 15 mg/kg and had a significantlyshorter t_1/2 in beagle dogs than in humans.

Key words

riluzole - pharmacokinetics - beagle dog - LC-MS/MS

• References

• 1 Donovan WH. Donald Munro Lecture. Spinal cord injury – past, present, and future. J Spinal Cord Med 2007; 30: 85-100
• 2 Cox A, Varma A, Banik N. Recent advances in the pharmacologic treatment of spinal cord injury. Metab Brain Dis 2015; 30: 473-482
• 3 Schwartz G, Fehlings MG. Secondary injury mechanisms of spinal cord trauma: A novel therapeutic approach for the management of secondary pathophysiology with the sodium calcium blocker riluzole. Prog Brain Res 2002; 137: 177-190
• 4 Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991; 75: 15-26
• 5 Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. CMAJ 2013; 185: 485-492
• 6 Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001; 94 2 Suppl 245-256
• 7 Bensimon G, Laomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591
• 8 Gutierrez J, Federici T, Peterson B. et al. Development of intrathecal riluzole: A new route of administration for the treatment of amyotrophic lateral sclerosis patients. Neurosurgery 2016; 63 1 Suppl 193
• 9 Jehle T, Bauer J, Blauth E. et al. Effects of riluzole on electrical evoked neurotransmitter release. Br J Pharmacol 2000; 130: 1227-1234
• 10 Obinu MC, Reibaud M, Blanchard V. et al. Neuroprotective effect of riluzole in a primate model of Parkinson’s disease behavioral and histological evidence. Mov Disord 2002; 17: 13-19
• 11 Chow DSL, Teng Y, Toups EG. et al. Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine 2012; 17: 129-140
• 12 Grossman RG, Fehlings MG, Frankowski RF. et al. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma 2014; 31: 239-255
• 13 Liboux A, Cachia JP, Kirkesseli S. et al. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. Journal of Clinical Pharmacology 1999; 39: 480-486
• 14 Bryson HM, Fulton B, Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996; 52: 549-563
• 15 Jin-Chao M, Chun-Fen L. Study of pharmacokinetics and in vitro-in vivo correlation of riluzole tablets in beagle dogs. Yi Yao Dao Bao 2014; 33: 1149-1153
• 16 Agência Nacional de Vigilância Sanitária (ANVISA). Resolution RE nº 899/03. Brazil, 2003.
• 17 Food and Drug Administration (FDA) . Guidance for industry bioanalytical method validation. USA: 2001
• 18 Bruno R, Vivier N, Montay G. et al. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Ther 1997; 62: 518-526
• 19 Le Liboux A, Lefebvre P, Le Roux Y. et al. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol 1997; 37: 820-827
• 20 Sanderink G, Bournique B, Stevens J. et al. Involvement of human cytochrome P450 isoenzymes in the hepatic metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997; 282: 1465-1472